BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8786006)

  • 1. Course of pseudocholinesterase isozymes during an acute phase in Crohn's disease.
    Novacek G; Reinisch W; Vogelsang H; Kapiotis S; Gmeiner B
    Digestion; 1996; 57(2):90-4. PubMed ID: 8786006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular forms of pseudocholinesterase in patients with Crohn's disease.
    Novacek G; Vogelsang H; Maier-Dobersberger T; Kapiotis S; Lochs H; Gmeiner B
    Digestion; 1993; 54(4):243-7. PubMed ID: 8243837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease?
    Novacek G; Vogelsang H; Schmidt B; Lochs H
    Wien Klin Wochenschr; 1993; 105(4):111-5. PubMed ID: 8451851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
    Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J
    Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
    Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
    Sacco R; Romano A; Mazzoni A; Bertini M; Federici G; Metrangolo S; Parisi G; Nencini C; Giampietro C; Bertoni M; Tumino E; Scatena F; Bresci G
    J Crohns Colitis; 2013 Dec; 7(12):e692-7. PubMed ID: 23870727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of Crohn's disease following corticosteroid-induced remission.
    Papi C; Festa V; Leandro G; Moretti A; Tanga M; Koch M; Capurso L
    Am J Gastroenterol; 2007 Apr; 102(4):814-9. PubMed ID: 17222316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
    Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The steroid resistance of Crohn's disease.
    Mingrone G; DeGaetano A; Pugeat M; Capristo E; Greco AV; Gasbarrini G
    J Investig Med; 1999 Jul; 47(6):319-25. PubMed ID: 10431487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
    Gong JF; Niu LY; Wei XW; Zhu WM; Li N; Li JS
    Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1213-7. PubMed ID: 19781164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease.
    Vogelsang H; Hamwi A; Ferenci P
    Digestion; 1996; 57(1):11-5. PubMed ID: 8626042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.